Cargando…
Epithelial Ovarian Cancer—Varied Treatment Results
Ovarian cancer (OC) is the eighth most common cancer worldwide and is usually diagnosed in advanced stages. Despite many available data, no treatment results have been reviewed in Poland. This study enrolled 289 first-time patients treated between 2018 and 2021 by the Department of Oncology of the P...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379362/ https://www.ncbi.nlm.nih.gov/pubmed/37510484 http://dx.doi.org/10.3390/healthcare11142043 |
_version_ | 1785079998087954432 |
---|---|
author | Millert-Kalińska, Sonja Przybylski, Marcin Pruski, Dominik Stawicka-Niełacna, Małgorzata Mądry, Radosław |
author_facet | Millert-Kalińska, Sonja Przybylski, Marcin Pruski, Dominik Stawicka-Niełacna, Małgorzata Mądry, Radosław |
author_sort | Millert-Kalińska, Sonja |
collection | PubMed |
description | Ovarian cancer (OC) is the eighth most common cancer worldwide and is usually diagnosed in advanced stages. Despite many available data, no treatment results have been reviewed in Poland. This study enrolled 289 first-time patients treated between 2018 and 2021 by the Department of Oncology of the Poznań University of Medical Sciences (SKPP). The relationships among starting treatment in our centre, the type of first intervention, and the final decision were significant (p < 0.001). Patients in the SKPP group were more likely to primarily have a laparoscopy and less likely to have an exploratory laparotomy. Neoadjuvant chemotherapy (NACT) after a laparotomy was less often a final decision among SKPP patients (9% vs. 22%), in contrary to NACT after a laparoscopy (23% vs. 4%). Factors affecting the shortening of progression-free survival (PFS) were an advanced stage of the disease, a histopathological diagnosis, the type of cytoreduction, and the final decision. Significance according to the final decision was revealed for PDS vs. NACT after a laparotomy (p < 0.001) and for PDS vs. NACT after a laparoscopy (p = 0.011). Our study supports the benefits of treating ovarian cancer in an oncology centre with a high patient throughput. Further observations might also answer the question about overall survival (OS). |
format | Online Article Text |
id | pubmed-10379362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103793622023-07-29 Epithelial Ovarian Cancer—Varied Treatment Results Millert-Kalińska, Sonja Przybylski, Marcin Pruski, Dominik Stawicka-Niełacna, Małgorzata Mądry, Radosław Healthcare (Basel) Article Ovarian cancer (OC) is the eighth most common cancer worldwide and is usually diagnosed in advanced stages. Despite many available data, no treatment results have been reviewed in Poland. This study enrolled 289 first-time patients treated between 2018 and 2021 by the Department of Oncology of the Poznań University of Medical Sciences (SKPP). The relationships among starting treatment in our centre, the type of first intervention, and the final decision were significant (p < 0.001). Patients in the SKPP group were more likely to primarily have a laparoscopy and less likely to have an exploratory laparotomy. Neoadjuvant chemotherapy (NACT) after a laparotomy was less often a final decision among SKPP patients (9% vs. 22%), in contrary to NACT after a laparoscopy (23% vs. 4%). Factors affecting the shortening of progression-free survival (PFS) were an advanced stage of the disease, a histopathological diagnosis, the type of cytoreduction, and the final decision. Significance according to the final decision was revealed for PDS vs. NACT after a laparotomy (p < 0.001) and for PDS vs. NACT after a laparoscopy (p = 0.011). Our study supports the benefits of treating ovarian cancer in an oncology centre with a high patient throughput. Further observations might also answer the question about overall survival (OS). MDPI 2023-07-17 /pmc/articles/PMC10379362/ /pubmed/37510484 http://dx.doi.org/10.3390/healthcare11142043 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Millert-Kalińska, Sonja Przybylski, Marcin Pruski, Dominik Stawicka-Niełacna, Małgorzata Mądry, Radosław Epithelial Ovarian Cancer—Varied Treatment Results |
title | Epithelial Ovarian Cancer—Varied Treatment Results |
title_full | Epithelial Ovarian Cancer—Varied Treatment Results |
title_fullStr | Epithelial Ovarian Cancer—Varied Treatment Results |
title_full_unstemmed | Epithelial Ovarian Cancer—Varied Treatment Results |
title_short | Epithelial Ovarian Cancer—Varied Treatment Results |
title_sort | epithelial ovarian cancer—varied treatment results |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10379362/ https://www.ncbi.nlm.nih.gov/pubmed/37510484 http://dx.doi.org/10.3390/healthcare11142043 |
work_keys_str_mv | AT millertkalinskasonja epithelialovariancancervariedtreatmentresults AT przybylskimarcin epithelialovariancancervariedtreatmentresults AT pruskidominik epithelialovariancancervariedtreatmentresults AT stawickaniełacnamałgorzata epithelialovariancancervariedtreatmentresults AT madryradosław epithelialovariancancervariedtreatmentresults |